K. Y. Ding, Ji, W. C., Wu, J. S., Li, T., and Sheng, Y. Y.,
“Higher frequency of CD4+CD25high Treg cells in hemophilia patients with factor VIII inhibitor”, vol. 13, pp. 1774-1781, 2014.
The production of factor VIII inhibitor antibodies remains the most costly and serious complication in replacement therapy of hemophilia A. We investigated the clinical significance of CD4+CD25high T regulatory (Treg) cells in hemophilia patients. Our trial included 6 severe hemophilia A patients with factor VIII inhibitors, 6 hemophilia patients without inhibition of factor VIII, and 6 healthy persons (controls). Plasma factor VIII: c was measured by clotting assay.
